Hikma Pharmaceuticals Rating Reiterated by UBS AG (HIK)
Hikma Pharmaceuticals (LON: HIK)‘s stock had its “sell” rating reaffirmed by research analysts at UBS AG in a report released on Monday. They currently have a $11.35 (755 GBX) target price on the stock.
Hikma Pharmaceuticals opened at 935.4999 on Monday. Hikma Pharmaceuticals has a 52-week low of GBX 598.50 and a 52-week high of GBX 888.00. The stock’s 50-day moving average is currently GBX 728.8. The company’s market cap is £1.833 billion.
HIK has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Friday. They now have a $13.52 price target on the stock. Separately, analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from $14.10 to $15.16 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from $12.81 to $14.45 in a research note to investors on Thursday, February 14th. They now have a “buy” rating on the stock.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.